Health Condition 1: F322- Major depressive disorder, singleepisode, severe without psychotic features Health Condition 2: F320- Major depressive disorder, singleepisode, mild Health Condition 3: F321- Major depressive disorder, singleepisode, moderate Health Condition 4: F324- Major depressive disorder, singleepisode, in partial remission Health Condition 5: F325- Major depressive disorder, singleepisode, in full remission Health Condition 6: F328- Other depressive episodes Health Condition 7: F
Conditions
Interventions
Intervention1: Vortioxetine: Following baseline assessments, Vortioxetine will be initiated at a dose of 10 mg per day. Dose optimization will be guided by changes observed on the HDRS 17 scale. If Vo
Sponsors
Governement Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Peri menopausal and post menopausal female with diagnosis of depressive disorders as per ICD 11
Exclusion criteria
Exclusion criteria: 1.Co-morbid psychiatric conditions such as Schizophrenia, Bipolar Disorder, Obsessive-Compulsive Disorder (OCD), severe depression with psychotic feature, comorbid substance dependence, excluding nicotine and caffeine or exhibiting active suicidal ideation or behaviour. 2.Chronic neurological illnesses or unstable medical conditions. 3.Intellectual Disability. 4.Those who have undergone Cognitive Behavioural Therapy, Cognitive Enhancement Therapy, or electroconvulsive therapy (ECT) within the last three months. 5. Pregnant or breastfeeding women or received hormonal replacement therapy (HRT) within 3 months prior to study enrolment. 6. Known allergy or hypersensitivity reaction to study drugs. 7.Premature menopause (before age of 40 year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess and compare the clinical effectiveness of Vortioxetine and Paroxetine in treatment of perimenopausal and postmenopausal depressionTimepoint: Baseline,2 weeks, 4 weeks, 6 weeks,10 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess & compare the effectiveness of Vortioxetine & Paroxetine on vasomotor & cognitive symptoms in perimenopausal & postmenopausal women with depression. To evaluate tolerability & side effect profile of Vortioxetine & Paroxetine in this demographic. To assess & compare the effectiveness of Vortioxetine & Paroxetine on quality of life. Timepoint: Baseline, 2 weeks, 4 weeks, 6 weeks, 10 weeks | — |
Countries
India
Contacts
Public ContactDr RITU
GOVERNMENT MEDICAL COLLEGE AND HOSPITAL, SECTOR 32, CHANDIGARH
Outcome results
None listed